Research and Development

The GAP vaccine is unique in that it is a whole-parasite vaccine yielding an advantage in conferring immunity towards multiple sites of the parasite, not just isolated parts as occurs in current sub-unit malaria vaccine candidates.

GAP vaccine Phase 1 safety trials have used P. falciparum parasites that are cultured in mosquito salivary glands and then tediously extracted by hand.  This is not a viable way to produce the quantities of parasites required or to produce clinical grade material for vaccines.  MalarVx is developing scalable in vitro culturing systems for clinical-grade P. falciparum parasite that will deliver the quantities required to produce millions of doses.

Additionally, we are working to optimize the storage conditions for transporting a whole-parasite vaccine to areas of the world with poor transportation infrastructure and limited storage support options.